This Article Full Text Full Text (PDF) All Versions of this Article: 36/10/2289    most recent 01.STR.0000181081.09262.e1v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Serebruany, V. L. Articles by Hanley, D. F. Search for Related Content PubMed PubMed Citation Articles by Serebruany, V. L. Articles by Hanley, D. F. Related Collections Platelet function inhibitors Antiplatelets Platelets

(Stroke. 2005;36:2289.)
© 2005 American Heart Association, Inc.

Research Reports

Effects of Clopidogrel and Aspirin in Combination Versus Aspirin Alone on Platelet Activation and Major Receptor Expression in Patients After Recent Ischemic Stroke

For the Plavix Use for Treatment of Stroke (PLUTO-Stroke) Trial

Victor L. Serebruany, MD, PhD; Alex I. Malinin, MD; Wendy Ziai, MD; Alex N. Pokov, MD; Deepak L. Bhatt, MD; Mark J. Alberts, MD Dan F. Hanley, MD

From the HeartDrug Research Laboratories (V.L.S., A.I.M., A.N.P.), Towson, Md; Johns Hopkins University (W.Z., D.F.H.), Baltimore, Md; Cleveland Clinic (D.L.B.), Cleveland, Ohio; and Northwestern University (M.J.A.), Chicago, Ill.

Correspondence to Victor L. Serebruany, MD, PhD, HeartDrug Research Laboratories, Osler Medical Center, 7600 Osler Dr, Suite 307, Towson, MD, 21204. E-mail Heartdrug{at}aol.com

Background and Purpose— Clopidogrel is widely used in patients after recent ischemic stroke; however, its ability to yield additional antiplatelet protection on top of aspirin has never been explored in a controlled study. To determine whether clopidogrel with aspirin (C+ASA) will produce more potent platelet inhibition than aspirin alone (ASA) in patients after ischemic stroke, we conducted the Plavix Use for Treatment of Stroke trial.

Methods— Seventy patients after ischemic stroke were randomly assigned to C+ASA or ASA groups. Platelet studies included aggregometry; cartridge-based analyzers; expression of PECAM-1, P-selectin, GP IIb/IIIa (antigen and activity), vitronectin receptor, and formation of platelet-leukocyte microparticles by flow cytometry. Platelet tests were performed at baseline and after 30 days after randomization.

Results— There were no deaths, hospitalizations, or serious adverse events. There were no differences in the baseline platelet characteristics between C+ASA and ASA groups, or significant changes in platelet parameters in the ASA group, except diminished collagen-induced aggregation (P=0.001). In contrast, therapy with C+ASA resulted in a significant inhibition of platelet activity assessed by ADP- (P=0.00001) and collagen-induced (P=0.02) aggregation; closure time prolongation (P=0.03), and reduction of platelet activation units with Ultegra (P=0.00001); expression of PECAM-1 (P=0.01), and GP IIb/IIIa activity with PAC-1 (P=0.02) when compared with ASA group. Therapy with C+ASA also resulted in the reduced formation of platelet–leukocyte microparticles (P=0.02).

Conclusion— Treatment with C+ASA for 1 month provides significantly greater inhibition of platelet activity than ASA alone in patients after recent ischemic stroke in the frame of the small randomized trial.

Key Words: aspirin • clinical trial • clopidogrel • platelets • stroke

This article has been cited by other articles:

				T Geisler, M Kapp, K Gohring-Frischholz, K Daub, C Dosch, B Bigalke, H Langer, C Herdeg, and M Gawaz Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease Heart, June 1, 2008; 94(6): 743 - 747. [Abstract] [Full Text] [PDF]

				V. Thijs, R. Lemmens, and S. Fieuws Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke Eur. Heart J., May 1, 2008; 29(9): 1086 - 1092. [Abstract] [Full Text] [PDF]

				S. Muller-Schunk, J. Linn, N. Peters, M. Spannagl, M. Deisenberg, H. Bruckmann, and T.E. Mayer Monitoring of Clopidogrel-Related Platelet Inhibition: Correlation of Nonresponse with Clinical Outcome in Supra-Aortic Stenting AJNR Am. J. Neuroradiol., April 1, 2008; 29(4): 786 - 791. [Abstract] [Full Text] [PDF]

				O. Morel, F. Toti, B. Hugel, B. Bakouboula, L. Camoin-Jau, F. Dignat-George, and J.-M. Freyssinet Procoagulant Microparticles: Disrupting the Vascular Homeostasis Equation? Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2594 - 2604. [Abstract] [Full Text] [PDF]

				V L Serebruany, M G Midei, H Meilman, A I Malinin, and D R Lowry Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. Postgrad. Med. J., June 1, 2006; 82(968): 404 - 410. [Abstract] [Full Text] [PDF]